首页> 外国专利> PROBENECID FOR TREATING CARDIOMYOPATHY, SYSTOLIC CARDIAC DYSFUNCTION AND THE SYMPTOMS OF CONGESTIVE HEART FAILURE

PROBENECID FOR TREATING CARDIOMYOPATHY, SYSTOLIC CARDIAC DYSFUNCTION AND THE SYMPTOMS OF CONGESTIVE HEART FAILURE

机译:治疗心律失常,心脏收缩功能异常和充血性心力衰竭的症状

摘要

Described herein are inventions directed to methods of treating a cardiac dysfunction and symptoms of cardiac dysfunction in a subject that includes administering an amount of probenecid effective to treat a symptom of cardiac dysfunction. Probenecid may be administered in at least one of an injection, orally, or transdermally. The amount of probenecid is sufficient to result in an improved performance on a standardized 6 minute walk test, an improved New York Heart Association (NYHA) classification, a lower diuretic dose requirement, a lower serum BNP levels, a normalization of serum sodium concentrations, and combinations thereof. Probenecid may be administered over a period of about 8 hours to about 24 hours. Probenecid may be used for short term treatments, i.e., less than a week, or it may be administered in a long term manner, i.e., over a period of weeks, months, or even years.
机译:本文描述了针对在受试者中治疗心脏功能障碍和心脏功能障碍症状的方法的发明,该方法包括给予有效治疗心脏功能障碍症状的丙磺舒。丙磺舒可通过注射中的至少一种口服或透皮给药。丙磺舒的量足以在标准的6分钟步行测试中改善性能,改善纽约心脏协会(NYHA)分类,降低利尿剂剂量要求,降低血清BNP水平,使血清钠浓度正常化,及其组合。丙磺舒可以在约8小时至约24小时的时间内施用。丙磺舒可以用于短期治疗,即少于一周,或者可以长期施用,即在数周,数月甚至数年的时间内施用。

著录项

  • 公开/公告号WO2014028042A1

    专利类型

  • 公开/公告日2014-02-20

    原文格式PDF

  • 申请/专利权人 UNIVERSITY OF CINCINNATI;

    申请/专利号WO2012US60990

  • 发明设计人 RUBINSTEIN JACK;JONES W. KEITH;

    申请日2012-10-19

  • 分类号A61K31/195;A61P9/04;

  • 国家 WO

  • 入库时间 2022-08-21 15:51:38

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号